MURRYSVILLE, Pennsylvania—Philips, a provider of sleep health technology, announced that Philips Respironics DreamStation BiPAP AVAPS devices are available for sale in the United States for new set-ups for patients with obstructive sleep apnea (OSA) and respiratory impairment, who are both >7 years of age and weighing 40-66 pounds.
The DreamStation BiPAP AVAPS devices provide respiratory support to lower-weight patient populations. The company said the availability of the devices will help address critical care gaps and supply challenges in the U.S.
“Patient safety is at the heart of everything we do, and expanding access to advanced, reliable care is essential,” said Sam Talya, business category leader, therapy platforms, sleep and respiratory care at Philips. “The availability of DreamStation BiPAP AVAPS devices in the U.S. for lower-weight patients supports a limited patient population. It is a signal of our commitment to ensure access to safe, effective respiratory solutions for patients who need them most.”
Devices will be available for purchase only to Philips customers who meet certain distribution control and traceability requirements.
DreamStation devices with the new silicone sound-abatement foam have been subject to testing in accordance with the applicable industry testing standards. Philips said it is confident these devices will help customers support the needs of its lower-weight patients.
For more information about the DreamStation BiPAP AVAPS devices, visit the DreamStation BiPAP AVAPS noninvasive ventilator webpage.